Pharmacokinetics and tolerance of single- and multiple-dose oral and intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 5, 2003, Pages 1239-1246

  Stalker, Dennis J ^a   Jungbluth, Gail L ^a   Hopkins, Nancy K ^a   Batts, Donald H ^b  

^a PFIZER INC   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Clinical trial; Gram positive; Linezolid; Oxazolidinones; Pharmacokinetics; Volunteers

Indexed keywords

ANTIBIOTIC AGENT; LINEZOLID; OXAZOLIDINONE DERIVATIVE; PLACEBO; PROTEIN SYNTHESIS INHIBITOR;

ADULT; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TOLERANCE; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE DRUG DOSE; NAUSEA; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SKIN DISEASE; THROMBOCYTOPENIA; TONGUE DISEASE; URINALYSIS;

ACETAMIDES; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ALGORITHMS; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; OXAZOLIDINONES;

EID: 0038440756     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg180     Document Type: Article

References (22)

1. Mutnick, A. H., Biedenbach, D. J., Turnidge, J. D. & Jones, R. N. (2002). Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. Diagnostic Microbiology and Infectious Disease 43, 65-73.
2. Ballow, C. H., Jones, R. N., Biedenbach, D. J. & the North American ZAPS Research Group. (2002). A multicenter evaluation of linezolid antimicrobial activity in North America. Diagnostic Microbiology and Infectious Disease 43, 75-83.
3. Noskin, G. A., Siddiqui, F., Stosor, V., Hacek, D. & Peterson, L. R. (1999). In vitro activities of linezolid against important Gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrobial Agents and Chemotherapy 43, 2059-62.
4. von Eiff, C. & Peters, G. (1999). Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci. Journal of Antimicrobial Chemotherapy 43, 569-73.
5. Zurenko, G. E., Yagi, B. H., Schaadt, R. D., Allison, J. W., Kilburn, L. O., Glickman, S. E. et al. (1996). In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrobial Agents and Chemotherapy 40, 839-45.
6. Swaney, S. M., Aoki, H., Ganoza, M. C. & Shinabarger, D. L. (1998). The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrobial Agents and Chemotherapy 42, 3251-5.
7. Dresser, L. D. & Rybak M. J. (1998). The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy 18, 456-62.
8. Cammarata, S. K., Schueman, L. K., Timm, J. A., Hempsall, K. A., Chang, W., Oliphant, T. H. et al. (2000). Oral linezolid in the treatment of community-acquired pneumonia: a phase III trial. In Program and Abstracts of the American Thoracic Society, Toronto, Ontario, Canada, 2000. Abstract E73, p. 654. American Thoracic Society, New York, NY, USA.
9. San Pedro, G. S., Cammarata, S. K., Oliphant, T. H. & Todisco, T. (2002). Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia. Scandinavian Journal of Infectious Diseases 10, 720-8.
10. Hau, T. (2002). Efficacy and safety of linezolid in the treatment of skin and soft tissue infections. European Journal of Clinical Microbiology and Infectious Diseases 21, 491-8.
11. Hartman, C. S., Leach, T. S., Kaja, R. W., Schaser, R. J. & Todd, W. M. (2000). Linezolid in the treatment of vancomycin-resistant enterococcus: a dose comparative, multicenter phase III trial. In Program and Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 2000. Abstract 2235, p. 488. American Society for Microbiology, Washington, DC, USA.
12. Stevens, D. L., Herr, D., Lampiris, H., Hunt, J. L., Batts, D. H. & Hafkin, B. (2002). Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clinical Infectious Diseases 34, 1481-90.
13. Rubinstein, E., Cammarata, S. K., Oliphant, T. H., Wunderink, R. G. & the Linezolid Nosocomial Pneumonia Study Group. (2001). Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clinical Infectious Diseases 32, 402-12.
14. Stevens, D. L., Smith, L. G., Bruss, J. B., McConnell-Martin, M. A., Duvall, S. E., Todd, W. M. et al. (2000). Randomized comparison of linezolid (PNU-100766) versus oxacillin/dicloxacillin for the treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy 44, 3408-13.
15. Gibaldi, M. & Perrier, D. (1982). Pharmacokinetics, 2nd edn. Marcel Dekker, New York, NY, USA.
16. Welshman, I. R., Sisson, T. A., Jungbluth, G. L., Stalker, D. J. & Hopkins, N. K. (2001). Linezolid absolute bioavailability and the effect of food on oral bioavailability. Biopharmaceutics and Drug Disposition 22, 91-7.
17. Zurenko, G. E., Gibson, J. K., Shinabarger, D. L., Aristoff, P. A., Ford C. W. & Tarpley, G. W. (2001). Oxazolidinones: a new class of antibacterials. Current Opinions in Pharmacology 1, 470-6.
18. Welshman, I. R., Stalker, D. J. & Wajszczuk, C. P. (1998). Assessment of absolute bioavailability and evaluation of the effect of food on oral bioavailability of linezolid. Antiinfective Drugs and Chemotherapy 16, Suppl. 1, 54.
19. 14C]linezolid to healthy human subjects. Drug Metabolism and Disposition 29, 1136-45.
20. Andes, D., Van Ogtrop, M. L., Peng, J. & Craig, W. A. (2002). In vivo pharmacodynamic activity of a new oxazolidinone (Linezolid). Antimicrobial Agents and Chemotherapy 46, 3484-9.
21. Perry, C. M. & Jarvis, B. (2001). Linezolid: a review of its use in the management of serious gram-positive infections. Drugs 61, 525-51.
22. Gerson, S. L., Kaplan, S. L., Bruss, J. B., Arellano, F. M., Hafkin, B. & Kuter, D. J. et al. (2002). Hematologic effects of linezolid: summary of clinical experience. Antimicrobial Agents and Chemotherapy 46, 2723-6.